Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 16/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4640806 | 0.75 | POLB (0.36) | KDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL4639669 | 0.71 | BACE1 (0.50) | BACE1KDM4E | |
| SCHEMBL6403829 | 0.68 | BACE1 (0.49) | BACE1KDM4E | |
| SCHEMBL11102202 | 0.67 | GAA (0.41) | — | |
| SCHEMBL27370401 | 0.66 | BACE1 (0.47) | BACE1KDM4EALDH1A1 | |
| SCHEMBL27794355 | 0.66 | BACE1 (0.43) | BACE1KDM4EALDH1A1 | |
| SCHEMBL5662165 | 0.65 | BACE1 (0.46) | BACE1KDM4E | |
| SCHEMBL5334890 | 0.65 | BACE1 (0.58) | BACE1KDM4EALDH1A1 | |
| SCHEMBL8264939 | 0.64 | BACE1 (0.61) | BACE1KMT2AALDH1A1 | |
| SCHEMBL1126152 | 0.63 | SCN3A (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080318985-A1 | Novel 2-Aminopyrimidinone Or 2-Aminopyridinone Derivatives and Their Use | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | disclosed |
| US-20080318985-A1 | Novel 2-Aminopyrimidinone Or 2-Aminopyridinone Derivatives and Their Use | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | disclosed |
| US-20080318985-A1 | Novel 2-Aminopyrimidinone Or 2-Aminopyridinone Derivatives and Their Use | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | disclosed |
| EP-1951682-A1 | NOVEL 2-AMINOPYRIMIDINONE OR 2-AMINOPYRIDINONE DERIVATIVES AND THEIR USE | Astra Zeneca AB (SE) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007058582-A1 | NOVEL 2-AMINOPYRIMIDINONE OR 2-AMINOPYRIDINONE DERIVATIVES AND THEIR USE | ASTRAZENECA AB (SE) | 2007-05-24 | — | — | WO | disclosed |
| WO-2007058582-A1 | NOVEL 2-AMINOPYRIMIDINONE OR 2-AMINOPYRIDINONE DERIVATIVES AND THEIR USE | ASTRAZENECA AB (SE) | 2007-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318985-A1 | Novel 2-Aminopyrimidinone Or 2-Aminopyridinone Derivatives and Their Use | PSEN2, PSEN1, GRIN2D | BACE1 12/4885KDM4E 1484/4885MEN1 3800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.